Expert Advice 20 Mar 2023
Nine tips to succeed in pharma-biotech partnerships
The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it…
Ablynx
- Latest Posts
News and Trends 30 Jul 2019
Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides
The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired…
News and Trends 4 Sep 2018
The EMA Approves the First Nanobody from Ablynx
Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in…
Interview 30 May 2018
How to Close a €3.9B Acquisition Deal for Your Biotech Company
Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal…
ADVERTISEMENT
News and Trends 29 Jan 2018
Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B
Sanofi will acquire Ablynx and get its hands on the biotech's exciting Nanobody technology just months after the biotech joined…
More News! 9 Jan 2018
Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk
Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth…
Best in Biotech 9 Jan 2018
Happy 2018, Here Are the Top 9 European Biotech Companies To Watch
As the 2017 reports roll in, we're already turning our gaze to 2018. These are the top European biotech companies…
Best in Biotech 18 Dec 2017
Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017
Now that we've got the bad news out of the way, we're here to spread some Christmas cheer with the…
Interview 11 Dec 2017
Edwin Moses on how Ablynx has made it to the top of European biotech
Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the…
Best in Biotech 5 Dec 2017
Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017
Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the…
News and Trends 4 Oct 2017
Ablynx Launches $175M IPO on Wall Street After Phase III Success
Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue…
News and Trends 2 Oct 2017
Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder
Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood…
News and Trends 20 Jul 2017
Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies
Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune…
News and Trends 23 May 2017
Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic
Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis.…
News and Trends 30 Mar 2017
Merck Outsources the Development of its Nanobody for Psoriasis
Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase…
Best in Biotech 15 Mar 2017
What are the Best Countries to Recruit Biotech Talents in 2017?
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look…
ADVERTISEMENT
News and Trends 12 Jan 2017
An Antibody to reduce Hospitalizations of Children starts Phase IIb trials
Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx,…
Best in Biotech 11 Jan 2017
UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan
The world's biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are…
News and Trends 9 Aug 2016
Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie
Ablynx has disclosed 'compelling' results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time…
News and Trends 11 Jul 2016
Nanobody Phase II Results for Arthritis: Good but not good enough?
Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie…
